| Recruitment status | Main results already published |
| Unique ID issued by UMIN | UMIN000009082 |
| Receipt No. | R000010655 |
| Official scientific title of the study | Efficacy of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis. |
| Date of disclosure of the study information | 2012/10/10 |
| Last modified on | 2016/09/15 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Efficacy of recombinant human soluble thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis. | |
| Title of the study (Brief title) | Efficasy of recombinant thrombomodulin for AE-IPF. | |
| Region |
|
|
| Condition | ||
| Condition | acute exacerbation of idiopathic pulmonary fibrosis | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | The purpose of this study is to show the change of P/F ratio and D-dimer
of the patients with acute exacerbation of idiopathic pulmonary fibrosis, before and after 7days of administration of recombinant human soluble thrombomodulin and m-PSL pulse therapy. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | Phase I |
| Assessment | |
| Primary outcomes | The change of P/F ratio before and after 7days of administration of recombinant human soluble thrombomodulin. |
| Key secondary outcomes | 1.D-dimer value at the 1,4,8,15,29 hospital days.
2.P/F ratio at the 1,8,15,29 hospital days. 3.the survival rate at the 29 hospital days |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | The patients diagnosed as AE-IPF are treated with m-PSL pulse therapy and intravenous recombinant human soluble thrombomodulin (rhTM) within 24 hrs after the diagnosis. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | Patients admitted to Toho Univercity
Sakura hospital and diagnosed AE-IPF based on the ATS/ERS/JRS guidelines |
|||
| Key exclusion criteria | 1)A person having an infection of apparent activity
2)Those who have apparent congestive heart failure. 3) Those who have apneumothorax 4) Those who have athma 5) Those who have deep vein thrombosis to be treated. 6) Who has the possibility of pulmonary arterial thromboembolism 7) A person who has circulatory failure, renal failure, liver failure 8) Those who have intracranial hemorrhage, pulmonary hemorrhage, gastrointestinal bleeding 9)A person with a history of hypersensitivity to components of the thrombomodulin 10) Women who may be pregnant or are pregnant |
|||
| Target sample size | 10 | |||
| Research contact person | |
| Name of lead principal investigator | Yasuo Matsuzawa |
| Organization | Toho university |
| Division name | Division of Pneumology |
| Address | 564-1 Shimoshizu Sakura City, Chiba Prefecture 285-8741 |
| TEL | |
| Public contact | |
| Name of contact person | Yasuo Matsuzawa |
| Organization | Toho university |
| Division name | Division of Pneumology |
| Address | 564-1 Shimoshizu Sakura City, Chiba Prefecture 285-8741 |
| TEL | 043-462-8811 |
| Homepage URL | |
| yasuo23@sakura.med.toho-u.ac.jp | |
| Sponsor | |
| Institute | Toho university |
| Institute | |
| Department | |
| Funding Source | |
| Organization | None |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Main results already published | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete |
|
||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Published |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010655 |